![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Fierce Biotech News & Reports
Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
Clinical Data - Fierce Biotech
2025年1月28日 · Irish biotech GH Research has said the phase 2 win for its inhaled depression drug has “paved the way for future commercial success.”
Sanofi-backed radiopharma AdvanCell secures $112M series C
6 天之前 · The oversubscribed series C round was co-led by SV Health Investors, Sanofi Ventures, Abingworth and SymBiosis. Morningside—which led AdvanCell’s $18 million series B in 2022—and new ...
Vertex files FDA ask for next-gen cystic fibrosis candidate
2024年5月7日 · In the U.S., Vertex intends to use its FDA priority review voucher, which guarantees an expedited six-month review process. Other big updates from the biotech include resumed enrollment in a phase ...
Analysts hail Vera's kidney drug as potential 'functional cure'
2024年10月28日 · Evercore ISI analysts said in a note to investors that Vera “impressed with continued normalization of eGFR with just 0.6mL decline through 96 weeks, in line with the normal range.”
A cell therapy reckoning - Fierce Biotech
2024年5月31日 · The Fierce Biotech team published a four-part series this week exploring cell therapy, a modality that has faced clinical challenges, manufacturing constraints and multiple practice-changing events
Madrigal lands MASH nod. What's next for biotechs in pursuit?
2024年3月15日 · That’s exactly what happened Friday morning when the markets opened—at least for Madrigal, which jumped more than 16% to $283.55. Other companies in the space had more modest bumps, such as ...
Undaunted Vertex closes in on FDA nod for non-opioid pain drug
2024年10月28日 · Another way that Vertex veered from the competition was to begin testing on the Nav1.8 channel, the function of which is closely related to the Nav1.7, helping supply its power.
FDA approves Novocure’s tumor field therapy for metastatic NSCLC
2024年10月16日 · Novocure submitted Optune Lua for FDA review in NSCLC in December 2023, after also seeking a CE Mark approval in Europe. Around the same time—and following the field’s failure in a phase 3 ...
2024 Life Sciences Industry Outlook - Fierce Biotech
The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the ...